Cellectis exits two CAR-T programs for liver gene editing
Cellectis stops internal development of two donor-cell CAR-T cancer programs and redirects resources to two preclinical mRNA-based liver gene-editing programs targeting severe lipid disorders, citing a shrinking patient pool and growing competition in later-line oncology.
On September 14, Cellectis announced that its board had approved a strategic shift three days earlier: the company will stop internal development of lasme-cel and eti-cel, two CAR-T programs in which donor T-cells are engineered to recognize tumor cells. The company attributes this to improvements in earlier lines of cancer treatment, which have reduced the patient pool for later-line therapy and slowed trial enrollment. Competition is also growing from bispecific antibodies (drugs that bind two biological targets) and CAR-T therapies generated inside the patient's body. Cellectis continues to seek partners for both programs; existing cell therapy partnerships remain in place. The Cell Therapy page on Eternal Search covers this area of treatment.
The freed-up resources go into two preclinical liver gene-editing programs targeting severe lipid metabolism disorders. Both use the same delivery mechanism: mRNA, a temporary set of instructions for the editing system, is packaged in lipid nanoparticles (tiny fatty shells) and delivered to the liver.
.HEAL-101 targets the APOC3 gene to treat severe hypertriglyceridemia (very high blood triglyceride levels). In a mouse model with human liver cells, editing efficiency at the target site was approximately 55%, with an approximately 45% reduction in triglycerides; in a separate severe hypertriglyceridemia model, the reduction was approximately 76%. Exploratory trial data from China are expected in the second half of 2027.
.HEAL-201 targets the PCSK9 promoter (a DNA region that regulates gene activity) to treat severe hypercholesterolemia (very high cholesterol levels). In a mouse model with human liver cells, plasma PCSK9 levels fell by more than 90%. Trial data from China are expected in the first half of 2028.
Cellectis estimates the reorganization extends its cash runway into the second half of 2028.
Open the related Eternal Search page
Sources
[1] cellectis.com
Cellectis's decision is a concrete illustration of how improving standard-of-care in earlier treatment lines can contract trial enrollment downstream, making the business case for a pivot. The Cell Therapy glossary page on Eternal Search gives readers a grounded entry point for the approach Cellectis is stepping back from before the in vivo liver-editing pivot is explained.